OABI
OmniAb, Inc.
Set alert
- YTD
- +176.22%
- 1 year
- +242.95%
- Open
- 4.40
- Prev close
- 5.23
- Mkt cap
- 742.94M
- Vol
- 2.11M
- Avg vol
- 1.68M
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.39
- High
- 5.11
- Forward P/E
- -8.95
- Beta
- 0.44
- Short ratio
- 14.24
- Inst. own
- 68.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 4.00
- 200-d avg
- 4.38
- 1y target
- 9.63
Key statistics
- Market cap
- 422.34M
- Enterprise value
- 388.00M
- Trailing P/E
- 0.00
- Forward P/E
- -8.95
- PEG ratio
- 0.00
- Price / sales
- 20.69
- Price / book
- 1.44
- EPS (TTM)
- -0.62
- Beta
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 20.41M
- Revenue growth
- -23.80%
- Free cash flow
- -13.94M
- Total cash
- 59.38M
- Total debt
- 23.84M
- Return on equity
- -20.45%
- Shares outstanding
- 121.01M
- Short % of float
- 7.00%
- 50-day average
- 4.00
- 200-day average
- 4.38
Analyst view
Consensus: strong buy
- Target (low)
- 7.00
- Target (mean)
- 9.63
- Target (high)
- 12.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.09667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.16 | -0.02 | -14.29% |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | -0.13 | +0.05 | +27.78% |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.17 | -0.19 | -0.02 | -11.76% |
| May 9, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| Mar 20, 2024 | Dec 1, 2023 | -0.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Benchmark | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | Benchmark | reit | Buy | Buy |
| Aug 16, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | Benchmark | reit | Buy | Buy |
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- omniab.com
News
- OmniAb Q3 2026 Earnings Call Transcript
- OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
- OmniAb Q3 Earnings Call Highlights
- OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- OmniAb Q3 EPS $(0.12), Inline, Sales $3.993M Beat $3.492M Estimate
- OmniAb Raises FY2026 Sales Guidance from $32.000M-$36.000M to $35.000M-$39.000M vs $35.036M Est
- OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
- OmniAb to Participate in Upcoming Investor Conferences in November
- OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
Your note
Sign in to keep a note on OABI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVISTA CAPITAL MANAGING MEMBER V, LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 27, 2024 | 0 |
| BERKMAN CHARLES S | Officer | Sale | Dec 8, 2024 | 323,385 |
| BERTOZZI CAROLYN R | Director | Conversion of Exercise of derivative security | Oct 31, 2024 | 55,539 |
| BOYCE SARAH | Director | Conversion of Exercise of derivative security | Jun 17, 2024 | 68,381 |
| COCHRAN JENNIFER R. | Director | Conversion of Exercise of derivative security | Jul 11, 2024 | 115,274 |
| FOEHR MATTHEW W | Chief Executive Officer | Sale | Dec 8, 2024 | 3,714,450 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avista Capital Holdings, L.P. | 13.07% | 15,817,934 | 55.20M | Sep 29, 2024 |
| Janus Henderson Group PLC | 6.50% | 7,871,328 | 27.47M | Sep 29, 2024 |
| Blackrock Inc. | 5.97% | 7,223,549 | 25.21M | Sep 29, 2024 |
| Vanguard Group Inc | 4.29% | 5,191,685 | 18.12M | Sep 29, 2024 |
| Macquarie Group Limited | 3.57% | 4,323,100 | 15.09M | Sep 29, 2024 |
| Chicago Capital, LLC | 2.61% | 3,162,555 | 11.04M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Triton Fund | 4.07% | 4,923,678 | 17.18M | Sep 29, 2024 |
| Delaware Group Equity Fds V-Small Cap Core Fund | 2.38% | 2,879,892 | 10.05M | Aug 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.14% | 2,594,464 | 9.05M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.90% | 2,299,475 | 8.03M | Oct 30, 2024 |
| Janus Henderson Venture Fund | 1.78% | 2,159,960 | 7.54M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.29% | 1,555,657 | 5.43M | Sep 29, 2024 |